A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Clinical trial NCT06178991 · COMPLETED
Trial details
- NCT number
- NCT06178991
- Sponsor
- BioNTech SE
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-20
- Primary completion
- 2024-11-26
- Enrollment
- 8795
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.